Clinical trials · New York, NY
Age-Related Macular Degeneration clinical trials in New York
We’re tracking 22 recruiting age-related macular degeneration studies with a site in or near New York — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies near New York
- NCT07441642RecruitingPhase 2
Study of FWY003 for geographic atrophy in age-related macular degeneration
This trial tests an investigational drug FWY003 against a placebo to see if it can slow or stop the progression of geographic atrophy, a form of advanced age-related macular degeneration that causes vision loss.
New York, New YorkAges 50 years+ - NCT06541704RecruitingPhase 3
Study of pozelimab with cemdisiran for geographic atrophy
This trial tests a combination of two study drugs (pozelimab and cemdisiran) given as a shot under the skin to slow the progression of geographic atrophy, a type of advanced dry age-related macular degeneration that causes blind spots in central vision.
New York, New YorkAges 50–85 - NCT05481827Enrolling by invitationPhase 2
Safety follow-up for GT005 in geographic eye damage
This study checks the long-term safety of GT005, a treatment you received in an earlier study, for geographic atrophy related to age-related macular degeneration. It mainly asks you to come to follow-up visits and confirm how you are doing over time.
New York, New YorkAges 55 years+ - NCT06779773Recruiting
Study of avacincaptad pegol (Izervay) for geographic atrophy
This study looks at how avacincaptad pegol (brand name Izervay) works in real-world medical practice for people with geographic atrophy, a form of age-related macular degeneration that causes vision loss. If your doctor has already decided to treat you with this medicine, you may be able to join.
New York, New YorkAges Any age - NCT07064759RecruitingPhase 3
Gene therapy injection for wet age-related macular degeneration
This trial tests a one-time gene therapy injection (4D-150) for wet AMD. It might help reduce the need for frequent anti-VEGF eye injections by targeting the underlying cause of new blood vessel growth.
New York, New YorkAges 50 years+ - NCT07215390RecruitingPhase 2
Study of APL-3007 plus Syfovre for geographic atrophy
This trial tests whether a new drug called APL-3007, when added to your current Syfovre treatment, can slow the progression of geographic atrophy (an advanced form of dry age-related macular degeneration). It's for people who have already been on Syfovre for at least 6 months.
Long Island City, New YorkAges 60 years+ - NCT07084883Recruiting
AI system for early AMD detection
This trial tests an AI system designed to catch early signs of late age-related macular degeneration (AMD) before it's diagnosed. It's for people who haven't yet been diagnosed with AMD or treated for retinal disease.
Richmond Hill, New YorkAges 50 years+ - NCT07205887RecruitingPhase 2
Study of EYE103 for wet AMD or macular edema after BRVO
This trial tests an investigational drug called EYE103 injected into the eye to treat two conditions: wet age-related macular degeneration (AMD) or macular edema following a branch retinal vein occlusion (BRVO). It looks at how safe and effective the drug is for people who have not had treatment before or have not responded well to previous treatments.
Bloomfield, New JerseyAges 18 years+ - NCT07482176RecruitingPhase 3
Gene therapy trial for wet age-related macular degeneration
This trial tests a one-time gene therapy injection (IXO-vec) for people with wet age-related macular degeneration (nAMD). It aims to reduce the need for frequent eye injections by helping the eye make its own medicine to block the growth of harmful blood vessels.
Bloomfield, New JerseyAges 50 years+ - NCT04853251RecruitingPhase 4
Study of corneal cells after a ranibizumab eye implant
This trial checks how well corneal endothelial cells (cells that help keep the cornea clear) do in people with neovascular age-related macular degeneration (nAMD) who are treated with a port-delivery implant that releases ranibizumab. It also helps doctors understand whether this method changes corneal health and stays safe while controlling the eye disease.
Bloomfield, New JerseyAges 50 years+ - NCT03683251RecruitingPhase 3
Extension study for a refillable eye implant plus ranibizumab
This trial studies whether continuing treatment with a refillable eye implant (Port Delivery System) and ranibizumab injection helps control a specific type of wet macular degeneration. It’s mainly for people who already finished an earlier related study and are able to keep up with frequent eye checks and procedures.
Bloomfield, New JerseyAges 50 years+ - NCT07614776RecruitingPhase 3
New Eye Injection Treatment for Age-Related Macular Degeneration
This study tests whether a new eye injection called ABP 938 works as well as or better than the current standard treatment (Eylea) for wet age-related macular degeneration—a condition that causes vision loss in the center of your sight. You would receive injections into your eye every month for a year.
Bloomfield, New JerseyAges 50 years+ - NCT07496567RecruitingPhase 2/Phase 3
Study of EYE201 for wet age-related macular degeneration
This trial tests a new medicine, EYE201, for people with wet age-related macular degeneration (AMD) that has not been treated before. The study will see if this drug can help improve vision and slow down vision loss.
Bloomfield, New JerseyAges 50 years+ - NCT07630649RecruitingPhase 2
Gene therapy for wet age-related macular degeneration in second eye
This study tests a one-time gene therapy injection (ixoberogene soroparvovec) in the second eye of people with wet age-related macular degeneration who have already responded well to anti-VEGF injections. The goal is to see if this gene therapy can help preserve or improve vision in that eye.
Teaneck, New JerseyAges 50 years+ - NCT07446582Recruiting
AI camera test for wet AMD detection
This study tests a new AI-powered camera that takes special pictures of the back of the eye to find signs of wet age-related macular degeneration (AMD) more easily. It compares images from people with wet AMD and healthy volunteers to see if the AI can spot the disease early.
Woodbridge, New JerseyAges 40 years+ - NCT06659445RecruitingPhase 2
Study of ONL1204 for geographic atrophy in dry AMD
This study tests an investigational medicine called ONL1204 given as an injection into the eye for people with a form of advanced dry age-related macular degeneration called geographic atrophy. The goal is to see if it can slow vision loss.
Oceanside, New YorkAges 55 years+ - NCT07158775RecruitingPhase 1/Phase 2
BS01 gene therapy for dry age-related macular degeneration
This trial tests a new gene therapy, BS01, given as an eye injection. It is for people with advanced dry age-related macular degeneration (AMD) that has caused geographic atrophy—damage to the central part of the retina. The study aims to see if the treatment is safe and can help slow vision loss.
Edison, New JerseyAges 50–85 - NCT07007065RecruitingPhase 3
Study of a gene therapy for wet age-related macular degeneration
This trial tests a one-time gene therapy injection for wet AMD that may reduce the need for regular eye injections. It is for people who have already responded to anti-VEGF injections but want a longer-lasting treatment.
Little Silver, New JerseyAges 50 years+ - NCT03178149RecruitingPhase 1
Study of a new eye treatment for dry macular degeneration
This Phase 1 trial tests the safety and side effects of ASP7317 in older adults whose central vision is worsening from dry age-related macular degeneration (geographic atrophy). If you qualify, you would receive treatment in the study eye and be closely monitored for about a year.
New Brunswick, New JerseyAges 50 years+ - NCT05438732Recruiting
Test of an implanted eye device plus vision training for AMD
This study tests a device that is surgically implanted in the eye of people with late-stage age-related macular degeneration (AMD). It also uses vision training with a telescope-like tool to see if the treatment can improve day-to-day vision.
Eatontown, New JerseyAges 65 years+ - NCT07440225RecruitingPhase 2/Phase 3
Testing a new drug for wet macular degeneration
This trial tests a new medicine called EYE201/MK-8748 for people who have wet age-related macular degeneration (a condition where abnormal blood vessels grow under the retina). It's for those who haven't had treatment before and were diagnosed recently.
Hauppauge, New YorkAges 50 years+ - NCT03011541Recruiting
Stem cell treatment for damaged retina or optic nerve
This study looks at stem-cell treatment to help vision in adults whose retina or optic nerve damage is not expected to improve on its own. You may be a candidate if your eye exam shows documented, stable or slowly changing damage and you can safely complete follow-up eye visits.
Westport, ConnecticutAges 18 years+
Hear when a new Age-Related Macular Degeneration trial opens near New York, NY
We’ll email you when one opens near New York, NY — at most once a week, no account needed, unsubscribe anytime.
Age-Related Macular Degeneration trials in other cities
Where these studies are running near New York
Institutions with a site for the recruiting age-related macular degeneration studies listed above.
- Envision Ocular, LLC · 6 studies
- Long Island Vitreoretinal Consultants · 6 studies
- NJ Retina · 6 studies
- Ophthalmic Consultants of Long Island · 3 studies
- Adverum Clinical Site 171 · 2 studies
- Columbia University Irving Medical Center · 2 studies
- Connecticut Eye Consultants, P.C. · 2 studies
- Monmouth Retina Consultants · 2 studies
What taking part in a age-related macular degeneration study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting age-related macular degeneration studies in New York.
Common questions
- Are there age-related macular degeneration clinical trials near New York?
- Yes. We're currently tracking 22 recruiting age-related macular degeneration studies with a site near New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a age-related macular degeneration study near New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site near New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a age-related macular degeneration trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New age-related macular degeneration studies open near New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.